Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00692
|
|||||
| Drug Name |
Cefdinir
|
|||||
| Synonyms |
(-)-(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-oxime; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(2 (2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid; 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetamido]-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid; BMY 28488; CFDN; Cefdinir (JP15/USAN/INN); Cefdinir [USAN:INN]; Cefdinirum; Cefdinirum [INN-Latin]; Cefdinyl; Cefdirnir; Cefzon; Cefzon (TN); FK 482; FK-482; FR-80482; KS-1038; Omnicef; Omnicef (TN); Omnicef, FK-482, BMY-28488, PD 134393, CI-983, Cefdinir; PD 134393; PD-134393
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Bacterial infections [ICD11:1A00-1H0Z] | Approved | [1] | |||
| Therapeutic Class |
Antibiotics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C14H13N5O5S2
|
|||||
| Canonical SMILES |
C=CC1=C(N2C(C(C2=O)NC(=O)C(=NO)C3=CSC(=N3)N)SC1)C(=O)O
|
|||||
| InChI |
InChI=1S/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1
|
|||||
| InChIKey |
RTXOFQZKPXMALH-GHXIOONMSA-N
|
|||||
| CAS Number |
CAS 91832-40-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 395.4 | Topological Polar Surface Area | 212 | ||
| Heavy Atom Count | 26 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 10 | |||
| XLogP |
0
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10310
,103241607
,104253245
,114784936
,12013492
,124637292
,124757367
,124766167
,125164171
,125311797
,126592899
,126670303
,131330280
,134222573
,134337732
,135013391
,135693788
,136368001
,137003422
,143493270
,144075787
,144089123
,144115805
,144240157
,14805465
,14927923
,152090681
,152242898
,152344175
,160963880
,17193404
,25819898
,26612828
,26680572
,43527984
,46386833
,46505573
,47943747
,48169352
,49679095
,50050916
,50123150
,52583972
,56422579
,57371624
,7847980
,92124803
,92308050
,92729947
,93166985
|
|||||
| ChEBI ID |
CHEBI:3485
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OAT3 | Transporter Info | Organic anion transporter 3 | Substrate | [2] | |
| PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Cefdinir was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005 Oct 1;70(7):1104-13. | |||||
| 3 | Transporter-mediated drug delivery: recent progress and experimental approaches. Drug Discov Today. 2004 Aug 15;9(16):712-20. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.